The gene-editing therapy specialist is rising in prominence. CRISPR Therapeutics (CRSP -2.27%) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for Casgevy, a therapy for the rare blood diseases transfusion-dependent beta-thalassemia and sickle cell disease. Though that was an important milestone for the biotech, CRISPR Therapeutics remains unprofitable, and it is unlikely to launch another product in t ...